Skip to main content
. 2022 Sep 28;16:100442. doi: 10.1016/j.mtbio.2022.100442

Fig. 5.

Fig. 5

Antitumor effect of F/A@P-mediated MDT combined with CTLA4 blockade therapy in an orthotopic 4T1 bilateral tumor-bearing mouse model. (a) Schematic diagram of F/A@P-mediated MHT combined with CTLA4 blockade therapy to inhibit primary and distant tumors. (b) Digital photographs of the mice in the five groups at 0, 1, 7, 14 and 21 days after various treatments. (c) Primary tumor growth curves and the average primary tumor growth curve of the mice in each group (n ​= ​6). (d) Distant tumor growth curves and average distant growth curve in each group (n ​= ​6). (e) Primary tumor inhibition rates and (f) distant tumor inhibition rates of the mice in each group. (g) Body weights and (h) morbidity-free survival of the mice in each group. (i) Digital photographs and H&E staining images of representative pulmonary metastatic nodules (circles) from the mice in each group at the end of treatment (scale bars: 100 ​μm). (The data are shown as the mean ​± ​SD, n ​= ​6 per group; n.s. represents no significance, ∗p ​< ​0.05, ∗∗p ​< ​0.01, ∗∗∗p ​< ​0.001 in comparison with the control group, #p ​< ​0.05, ##p ​< ​0.01, ###p ​< ​0.001 in comparison with the F/A@P ​+ ​AMF group).